On this edition of “Ask Dr. J”, Dr. Russell Jaffe is asked if he has ever considered offering sublingual immuno-therapy as a conjunctive therapy for the ELISA/ACT allergen panel. Tune in to hear what Dr. J has to say!
Effective December 18, 2024, ELISA/ACT Biotechnologies will be temporarily closing for operational research and improvement
